IL6 and colitis: In our experimental model of colitis, RvD2 treatment consistently led to a significant reduction in the expression of key pro-inflammatory cytokines, including TNFα and IL6, across all tested concentrations (0.01 μM, 0.1 μM, and 0.3 μM).